<DOC>
	<DOCNO>NCT01527500</DOCNO>
	<brief_summary>The amendment design test safety efficacy lower high dos Intravitreal ( IVT ) LFG316 use single 18 successive monthly injection patient geographic atrophy ( GA ) . The study also provide information safety , tolerability , serum concentration pharmacodynamics single multiple IVT dose LFG316 .</brief_summary>
	<brief_title>Intravitreal LFG316 Patients With Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Diagnosis AMD Geographic atrophy least one eye ETDRS best correct visual acuity 60 letter bad ( ~â‰¤ 20/63 ) Retinal disease AMD History choroidal neovascularization Severe cataract History infectious uveitis endophthalmitis Eye surgery nonstudy eye within 30 day prior study Eye surgery IVT injection study eye within 90 day prior study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>geographic atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Blindness</keyword>
	<keyword>Drusen</keyword>
	<keyword>GA lesion</keyword>
</DOC>